Equities research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
PULM stock opened at $2.19 on Friday. The firm has a market cap of $8.00 million, a P/E ratio of -0.91 and a beta of 0.99. The firm’s fifty day moving average is $1.92 and its 200 day moving average is $1.89. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.84.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 EPS for the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%. The firm had revenue of $5.89 million for the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- How to Use the MarketBeat Stock Screener
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is a buyback in stocks? A comprehensive guide for investors
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Health Care Stocks Explained: Why You Might Want to Invest
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
